Table 1.
Demographic and clinical characteristics of participants.
| Characteristic | Total (n = 128) | Remission NMOSD (n = 43) |
Acute NMOSD 1 (n = 60) |
HCs (n = 25) |
P value | P1 value | P2 value | P3 value |
|---|---|---|---|---|---|---|---|---|
| Sex; n(%) | 0.831^ | – | – | – | ||||
| Male | 10 (7.81) | 4 (9.30) | 5 (8.33) | 1 (4.00) | ||||
| Female | 118 (92.19) | 39 (90.70) | 55 (91.67) | 24 (96.00) | ||||
| Age; Mean ± SD | 46.81 ± 12.63 | 50.93 ± 13.65 | 44.45 ± 12.67 | 45.40 ± 8.79 | 0.029△ | 0.027 | 0.182 | 0.944 |
| EDSS; M (Q1; Q3) | 3.00 (1.50; 4.50) | 2.50 (1.25,3.50) | 3.50 (2.00,6.50) | – | 0.027Z | – | – | – |
| Attacks; M (Q1; Q3) | 1.00 (0.00; 3.00) | 2.00 (1.00,3.00) | 1.00 (0.00,2.00) | – | 0.176Z | – | – | – |
| WBC; M (Q1; Q3) | 6.11 (4.88; 8.48) | 6.37 (4.93,7.78) | 6.54 (5.44,9.65) | 4.93 (4.32,5.84) | <.001 # | 0.318 | 0.005 | <0.001 |
| NEUT; M (Q1; Q3) | 3.81 (2.88; 5.42) | 3.85 (3.05,5.17) | 4.56 (3.69,7.16) | 2.66 (2.30,3.46) | <.001# | 0.071 | <0.001 | <0.001 |
| NLR; M (Q1; Q3) | 2.29 (1.72; 3.56) | 2.17 (1.63,3.32) | 2.73 (1.99,4.37) | 1.67 (1.13,2.02) | <.001# | 0.031 | 0.002 | <0.001 |
| PLR; M (Q1; Q3) | 145.09 (113.13; 196.80) | 134.74 (108.29,182.27) | 163.61 (121.84,215.15) | 145.07 (104.87,183.05) | 0.371# | – | – | – |
| MLR; M (Q1; Q3) | 0.22 (0.17; 0.30) | 0.24 (0.20,0.31) | 0.23 (0.17,0.32) | 0.16 (0.12,0.21) | <.001# | 0.297 | <0.001 | <0.001 |
| SII; M (Q1; Q3) | 580.98 (411.25; 907.67) | 535.96 (398.87,908.44) | 709.61 (537.09,1012.74) | 405.58 (259.78,523.33) | <.001# | 0.021 | 0.007 | <0.001 |
| SIRI; M (Q1; Q3) | 0.89 (0.56; 1.41) | 1.03 (0.70,1.60) | 1.10 (0.72,1.53) | 0.47 (0.32,0.59) | <.001# | 0.810 | <0.001 | <0.001 |
| IL-6; M (Q1; Q3) | 2.27 (0.75; 4.16) | 2.80 (1.81,4.73) | 2.04 (0.75,4.45) | 2.25 (1.77,3.05) | 0.215# | – | – | – |
| IgA; M (Q1; Q3) | 2.13 (1.66; 2.65) | 1.67 (1.34,2.18) | 2.18 (1.73,3.04) | 2.26 (1.78,2.55) | 0.004# | 0.003 | 0.005 | 0.751 |
| IgG; M (Q1; Q3) | 12.10 (8.84; 14.30) | 9.25 (7.02,11.30) | 12.60 (9.50,14.30) | 14.00 (11.90,14.90) | <.001# | 0.004 | <0.001 | 0.069 |
| IgM; M (Q1; Q3) | 0.93 (0.64; 1.36) | 0.78 (0.41,1.25) | 1.01 (0.66,1.38) | 1.04 (0.83,1.27) | 0.167# | – | – | – |
| C3; M (Q1; Q3) | 1.06 (0.94; 1.16) | 1.06 (0.85,1.17) | 1.04 (0.94,1.16) | 1.15 (0.98,1.19) | 0.235# | – | – | – |
| C4; M (Q1; Q3) | 0.22 (0.17; 0.28) | 0.19 (0.15,0.25) | 0.21 (0.17,0.28) | 0.27 (0.23,0.32) | <.001# | 0.311 | <0.001 | 0.001 |
| 25(OH)D; M (Q1; Q3) | 51.70 (39.92; 68.18) | 55.70 (48.60,70.50) | 49.80 (39.00,64.70) | – | 0.271Z | – | – | – |
| GFAP; M (Q1; Q3) | 85.32 (62.74; 140.46) | 80.04 (66.20,87.83) | 94.00 (59.34,191.69) | – | 0.331Z | – | – | – |
| Nfl; M (Q1; Q3) | 13.28 (6.60; 26.00) | 8.05 (5.70,13.77) | 17.29 (7.30,53.43) | – | 0.078Z | – | – | – |
△, ANOVA; #, Kruskal-waills test; ^, Fisher exact; Z, Mann-Whitney test.
SD, standard deviation; M, Median; Q1, 1st Quartile; Q3, 3st Quartile.
*P1, Comparison results between the remission phase group and the acute phase group; P2, comparison results between the remission phase group and HC group; P3, comparison results between the acute phase group and HC group [using post-hoc test (Dunn's test or Tukey's HSD test)].
Bold values indicate P < 0.05.